June 15, 2022 | Children’s Health Defense
On June 14, 2022, EPPC Fellow Dr. David Gortler was quoted by Children’s Health Defense’s publication The Defender on the vote by the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) vote to recommend Moderna’s Covid vaccine for children ages 6-17.
Dr. David Gortler is a pharmacologist, pharmacist, FDA and healthcare policy oversight fellow and FDA reform advocate at the Ethics and Public Policy Center in Washington, D.C.
In a public comment published on the Ethics and Public Policy Center’s website, Gortler said the FDA and its advisory panel have “maintained a highly non-scientific and casual attitude toward approving a vaccine whose short- and long-term effects on children are unclear.”
Gortler said the FDA has failed to address genotoxicity, teratogenicity, oncogenicity of COVID-19 vaccines and cardiovascular risk following vaccination, potential fertility issues and clinical effects of spike proteins in donated or transfused blood.
“Before parents consent to vaccinate their children against COVID, basic medical ethics requires that they be informed of exactly how safe that vaccine is,” Gortler said.
Four million doses must be administered to children 5 to 11 years of age to prevent a single ICU admission in the same age group, Gortler said.
“Assuming two doses per child, that means two million children must risk potentially serious side effects to prevent a single child from requiring intensive care due to COVID-19.”
Another analysis, by Kathy Dopp and Stephanie Seneff, Ph.D., shows COVID-19 vaccination increases a child’s risk of dying from infection.
“Children under 18 are also 51 times more likely to die from the vaccine than they are to die from COVID infection if not vaccinated,” Gortler said, citing the analysis. “In other words, there is no clinical or epidemiological justification for vaccination in this particular group.”